Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Clinical Outcomes with Alemtuzumab: 5-Year Follow-Up of Care-MS Ii

Raed Alroughani, Mohamed Al Jumah, Douglas L Arnold, Hans-Peter Hartung, Eva Havrdova, Jihad Said Inshasi, Jihad Said Inshasi, David H Margolin, Linda Kasten, D Alasdair S Compston